As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&...
“This is not ‘negotiation.’ It is tantamount to extortion,” Merck wrote in its s...
Merck sued the U.S. government, seeking an injunction to block the drug-price ne...
Oncologists accustomed to treating cancer with medicines have been slow to turn ...
Medicare has chosen a career official to temporarily lead its implementation of ...
New life science Ph.D. graduates who have kids or big loans, or are Black or fem...
“Seeing a drug emerge is one of the most exciting things that you can do,” said ...
There are scenarios where the benefits of masking in health care settings would ...
The first lesson we learned the hard way during the pandemic: Don't assume scien...
More than 230 people have retired from the FDA since Oct. 1.
Why do we get seasonal allergies? And why do they make us so miserable? STAT exp...
The FDA has removed a neurologist with financial ties to Biogen and Eisai from a...
“I think we need to vote," said the FDA's oncology chief, Richard Pazdur. "We ha...
UnitedHealth Group and its Optum division proposed to buy Amedisys for $3.3 bill...
“It's not just about profits. It certainly is not about us as individuals. It's ...
Proving a meaningful survival benefit for patients with a type of blood cancer r...
